Henry Uppal

Bachelor of Medicine and Bachelor of Science,  Toronto General - University Health Network 

Location: Germany

Consulting Services

Hospital-Pharmacy-Insurance Career Advice and Mentoring Data Science-Bioinformatics Research Consulting Legal Support

Areas Of Interest

Modifications, Co-Translational Protein Glaucomas, Uncompensative Postcommissurotomy Syndromes Disease, Bouillaud Resonance, Electron Spin Pressures, Maximum Respiratory Hydrophobicity Biological Indicators CI719 Trinitrobenzenesulfonic Acid Nervous System Diseases, Parasympathetic Ridzol Integrin, beta3A Th3 Cells Sunspot Pyruvate Decarboxylase Deficiency Medical Incident, Critical Protein Subunit Cross-Over Trials Averrhoa carambola Databases, DNA Sequence CapZ Actin Capping Protein, beta Subunit EIF-2beta DDAVP Continued Stay Reviews Atrophy, Gyrate Planning Theories Hybridization, Genetic Drugs, Anticarcinogenic Pneumorrhachi, Epidural Type Ia Hyperlipoproteinemias Reactions, Anniversary Open Spines Plannings, Community Health

Professional Narrative

Dr. Henry Uppal was born in DuBois, Pennsylvania and is a graduate of Villanova University. He obtained his medical degree at Thomas Jefferson University in Philadelphia. His residency was at Thomas Jefferson and its affiliated Wills Eye Hospital, and he completed his training with fellowships at the University of Connecticut incataract andcorneal surgery.

Dr. Uppal has thirty years’ experience in ophthalmic surgery,withspecialinterestin cataract surgery,corneal transplantation,andlaserrefractiveprocedures.Heisa founding member of Precision LASIK Group, Chief of Ophthalmology at The Hospital ofCentral Connecticut,andco-medical director of the Connecticut eye bank.


Employment

Assistant Professor, Harvard Med 2009
Director Medicine, Amgen 1987

Education

Director Medicine, Perelman School of Medicine 1991
Doctor of medicine, Yale School of Medicine 2009

Referees


Publications

Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019 Mar;18(3):175-196. doi: 10.1038/s41573-018-0006-z. PMID: 30622344; PMCID: PMC6410566.

Tang Z, Kong N, Zhang X, Liu Y, Hu P, Mou S, Liljeström P, Shi J, Tan W, Kim JS, Cao Y, Langer R, Leong KW, Farokhzad OC, Tao W. A materials-science perspective on tackling COVID-19. Nat Rev Mater. 2020;5(11):847-860. doi: 10.1038/s41578-020-00247-y. Epub 2020 Oct 14. PMID: 33078077; PMCID: PMC7556605.

Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019 Mar;18(3):175-196. doi: 10.1038/s41573-018-0006-z. PMID: 30622344; PMCID: PMC6410566.

Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020 Oct;19(10):673-694. doi: 10.1038/s41573-020-0075-7. Epub 2020 Aug 11. PMID: 32782413; PMCID: PMC7419031.


Grants,Awards and Certifications

Grants :

No Grants Mentioned !!

Awards & Prizes :


Languages

Language Proficiency :

Translation Services :